NCT05663866 2026-04-13
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.